



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/509128-Conf. #4053
				Filing Date	September 28, 2004
				First Named Inventor	GRACZYK
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	0102286.00154US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
↓	BA	EP-0 737 685	10-16-1996	Viaud et al.		
	BB	EP-1 106 621	06-13-2001	Fuji Photo Film Co., Ltd.		
	BC	WO-99/20624	04-29-1999	Hoffmann-La Roche		
	BD	WO-99/21859	05-06-1999	Glaxo Group Limited		
	BE	WO-00/35909	06-22-2000	Hoffman-LaRoche		
	BF	WO-00/35921	06-22-2000	Hoffman-LaRoche		
	BG	WO-00/56710	09-28-2000	Glaxo Group Limited		
	BH	WO-00/64872	11-02-2000	Vertex Pharmaceuticals Inc.		
	BI	WO-01/12609	02-22-2001	Signal Pharmaceuticals, Inc.		
	BJ	WO-01/47922	07-05-2001	Aventis Pharma Limited		
	BK	WO-01/49288	07-12-2001	Merck Frosst Canada & Co.		
	BL	WO-02/16359	02-28-2002	Glaxo Group Limited		
	BM	WO-02/081475	10-17-2002	Eisai Co., Limited		
	BN	WO-03/082869	10-09-2003	Eisai London Research Laboratories Limited		


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/S.L.	CA	CAO et al., "Distinct Requirements for p38 $\alpha$ and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death", <i>The Journal of Biological Chemistry</i> , Vol. 279, No. 34, pp. 35903-35913, 20 August 2004	
	CB	EILERS et al., "Direct Inhibition of c-Jun N-terminal Kinase in Sympathetic Neurons Prevents c-jun Promoter Activation and NGF Withdrawal-induced Death", <i>Journal of Neurochemistry</i> , Vol. 76, pp. 1439-1454, 2001	
	CC	EILERS et al., "Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons", <i>The Journal of Neuroscience</i> , Vol. 18, No. 5, pp. 1713-1724, 1 March 1998	
	CD	ESTUS et al., "Aggregated Amyloid- $\beta$ Protein Induces Cortical Neuronal Apoptosis and Concomitant "Apoptotic" Pattern of Gene Induction", <i>The Journal of Neuroscience</i> , Vol. 17, No. 20, pp. 7736-7745, 15 October 1997	
	CE	HAM et al., "A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against	

Examiner Signature	/Sun Jae Loewe/	Date Considered	01/01/2008
-----------------------	-----------------	--------------------	------------

5450114

US1DOCS 5450114v1



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/509128-Conf. #4053
				Filing Date	September 28, 2004
				First Named Inventor	GRACZYK
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0102286.00154US1

		Programmed Cell Death", <i>Neuron</i> , Vol. 14, pp. 927-939, May, 1995	
/S.L./	CF	HARPER et al., "Inhibitors of the JNK Signaling Pathway", <i>Drugs of the Future</i> , Vol. 26, No. 10, pp. 957-973, 2001	
	CG	LISNOCK et al., "Activation of JNK3 $\alpha$ 1 Requires Both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3 $\alpha$ 1", <i>Biochemistry</i> , Vol. 39, pp. 3141-3149, 2000	
	CH	WATSON et al., "Phosphorylation of c-Jun is Necessary for Apoptosis Induced by Survival Signal Withdrawal in Cerebellar Granule Neurons", <i>The Journal of Neuroscience</i> , Vol. 18, No. 2, pp. 751-762, 15 January 1998	
↓	CI	YOUNG et al., "Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site", <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 18, pp. 12116-12121, 2 May 1997	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

/Sun Jae Loewe/

01/01/2008

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5450114

US1DOCS 5450114v1